These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30815390)

  • 21. Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).
    Echarri MJ; Lopez-Martin A; Hitt R
    Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of molecular targeted therapy with radiation in head and neck cancer.
    Du Y; Peyser ND; Grandis JR
    Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer.
    Misiukiewicz K; Posner M
    J Comp Eff Res; 2013 Nov; 2(6):533-5. PubMed ID: 24236791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16, HPV, and Cetuximab: What Is the Evidence?
    Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
    Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Argiris A; Harrington KJ; Tahara M; Schulten J; Chomette P; Ferreira Castro A; Licitra L
    Front Oncol; 2017; 7():72. PubMed ID: 28536670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
    von der Grün J; Rödel F; Brandts C; Fokas E; Guckenberger M; Rödel C; Balermpas P
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.
    Szturz P; Vermorken JB
    Oral Oncol; 2020 Feb; 101():104492. PubMed ID: 31837576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecularly targeted therapy in head and neck cancer].
    Le Tourneau C
    Bull Cancer; 2010 Dec; 97(12):1453-66. PubMed ID: 21134823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.
    Soulières D; Licitra L; Mesía R; Remenár É; Li SH; Karpenko A; Chol M; Wang YA; Solovieff N; Bourdeau L; Sellami D; Faivre S
    Clin Cancer Res; 2018 Jun; 24(11):2505-2516. PubMed ID: 29490986
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
    Machiels JP; Schmitz S
    Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A new horizon in the treatment of head and neck cancer - anti-epidermal growth factor receptor monoclonal antibodies as novel options].
    Tahara M; Fujii M
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2489-507. PubMed ID: 23235168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent advances in molecular-targeted drugs in head and neck cancer].
    Tahara M
    Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
    Schmitz S; Machiels JP
    Curr Treat Options Oncol; 2016 Jul; 17(7):37. PubMed ID: 27262711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy plus EGFR inhibitors: synergistic modalities.
    Bossi P; Platini F
    Cancers Head Neck; 2017; 2():2. PubMed ID: 31093349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.